Trial Profile
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Anaplastic large cell lymphoma; Basal cell cancer; Carcinoma; Cutaneous T-cell lymphoma; Ductal carcinoma; Extramammary Paget disease; Lymphoma; Merkel cell carcinoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome; Skin cancer; Squamous cell cancer; T-cell lymphoma
- Focus Therapeutic Use
- 18 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.
- 02 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.